Lanzo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanzo

Quick Facts Summary

Property Description
Active ingredient Lansoprazole
Form Delayed-release capsules, orally disintegrating tablets, oral suspension
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Management of acid-related disorders
Origin Synthetic substituted benzimidazole

What Type of Medicine is Lanzo and How is it Classified?

Lanzo is a pharmaceutical preparation containing the active ingredient Lansoprazole, a powerful antisecretory compound used to manage acid-related disorders. Lansoprazole is chemically classified as a substituted benzimidazole and belongs to the Proton Pump Inhibitor (PPI) pharmacological class.

Lansoprazole's effectiveness is clinically recognized for its ability to provide potent and long-lasting control over gastric acid production. The drug is recognized by the World Health Organization under the ATC code A02BC03, confirming its classification as a therapeutic agent specifically designed to manage conditions characterized by high stomach acid output.

Lansoprazole Composition and Available Forms

The composition of the medicine features Lansoprazole as the single active ingredient, delivered primarily through the oral route of administration. A key differentiating factor for Lansoprazole products is the availability of an orally disintegrating tablet (ODT) form, offering an alternative to standard delayed-release capsules.

To guarantee the medicine's effectiveness, these forms are engineered with enteric-coated granules or pellets. This specialized technology is necessary because the active compound is highly sensitive to acid and must be protected from the harsh stomach environment until it reaches the small intestine for absorption, ensuring maximal therapeutic effect.

General Purpose: Why is a Proton Pump Inhibitor Used?

The general purpose of Lanzo is to provide significant, long-lasting relief from discomfort associated with hyperacidity by acting as a powerful gastric acid-pump inhibitor. For example, it is typically used for patients experiencing persistent heartburn or other severe symptoms related to high gastric acid output.

The medicine's core function is to achieve profound acid suppression by permanently blocking the final production of acid within the stomach lining cells. This mechanism helps to stabilize the chemical environment of the upper digestive tract, serving as the drug's overarching benefit.

What side effects are possible with Lanzo?

Possible side effects and safety information

The official safety documents for Lansoprazole (Lanzo) categorize possible adverse reactions primarily by frequency of occurrence and the physiological system affected.

Adverse Reaction Scope

Category Regulatory Summary
Common Side Effects Include those listed as affecting between 1% and 10% of patients, such as headache, dizziness, diarrhea, nausea, vomiting, abdominal pain, constipation, and skin rash.
System-Organ Classes Effects are listed across various systems, most frequently involving Gastrointestinal disorders (e.g., flatulence) and Nervous System disorders (e.g., dizziness, headache). Other noted systems include Skin and subcutaneous tissue disorders and Musculoskeletal disorders.
Serious Adverse Reactions Officially documented serious reactions include Acute Interstitial Nephritis (a type of kidney inflammation), severe Cutaneous Adverse Reactions (SCARs), and the risk of severe Hypomagnesaemia (low serum magnesium).

Regulatory Safety Patterns

Certain safety concerns are explicitly linked to the duration of use or patient-specific factors, as defined in regulatory labeling.

  • Duration-Dependent Risks: Long-term use (typically one year or longer) is associated with an increased regulatory risk for osteoporosis-related fractures (hip, wrist, or spine) and Hypomagnesaemia. Additionally, long-term daily therapy may lead to malabsorption of Vitamin B12.
  • Population-Specific Caution: Caution is noted for use in patients with Severe Hepatic Impairment due to potential changes in drug clearance. The orally disintegrating form may also contain phenylalanine, which is a concern for individuals with Phenylketonuria (PKU).
  • Other Constraints: The label notes that improvement in symptoms does not rule out the presence of a Gastric Malignancy. Therapy is also associated with an increased risk of Clostridium difficile Associated Diarrhea (CDAD) and may interfere with diagnostic tests for neuroendocrine tumors.

Overdose and Emergency Response

Lanzo Overdose and When to Seek Help

This section summarizes the official regulatory information regarding acute overdose with Lanzo (lansoprazole), based on government-authorized prescribing documents.


Documented Overdose Profile

Official labeling indicates that no consistently documented specific symptoms or characteristic adverse effects have been identified in cases of acute lansoprazole overdose. Notably, regulatory reports mention a patient who ingested a dose as high as 600 mg without experiencing any reported adverse events or clinical symptoms. Consequently, the regulatory profile focuses on standardized emergency protocols rather than a unique overdose syndrome.


Required Emergency Actions

Immediate emergency medical attention is strictly mandated in the event of any suspected overdose, irrespective of the presence of symptoms. The official instruction requires individuals to seek immediate medical attention and contact a Poison Control Center right away.


Management and Antidote Information

The established regulatory protocol dictates that no specific antidote is known for lansoprazole overdose. Management must therefore be symptomatic and supportive. Healthcare professionals may consider procedures to remove unabsorbed drug, such as gastric emptying or the use of activated charcoal. Furthermore, official prescribing information notes that lansoprazole is not significantly removed by hemodialysis.

Therapeutic Uses of Lanzo

Lanzo, containing lansoprazole, is considered relevant in the management of numerous conditions presenting with systemic or localized discomfort where excessive stomach acid may be the cause. The medicine is commonly used to help with acute or disruptive symptom patterns and is applied in addressing symptom clusters that may become intense or disruptive.

The therapeutic domain includes Gastro-Oesophageal Reflux Disease (GORD), which involves episodic or fluctuating manifestations like heartburn and acid reflux; Stomach and Duodenal Ulcers; Prophylaxis of ulcers associated with certain medications; and Zollinger-Ellison Syndrome, a rare condition marked by increased physiological stress. For these common clinical scenarios, the medicine may assist with supportive relief.

Quick Fact: Supports comfort during Heartburn

In all these cases, the medication contributes to easing the overall symptom load by supporting the patient during difficult episodes. This supportive action helps maintain a sense of stability when symptoms are more noticeable, and provides support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lanzo?

This section outlines the official population eligibility and restriction rules for Lanzo (Lansoprazole) as defined by government regulatory authorities.


Populations Approved for Use

Adults are approved for all label-listed uses. Pediatric patients aged 1 to 17 years are approved for the short-term treatment of symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE).


Absolute Contraindications (Who Must Not Use)

Lanzo is formally prohibited for individuals with a known severe hypersensitivity to Lansoprazole or any of the product's components. Use is also contraindicated if the patient is taking the HIV medicine atazanavir (or rilpivirine) due to reduced drug efficacy. Patients with certain rare hereditary problems, such as fructose intolerance, must also not use certain formulations.


Conditional Use and Restrictions

  • Hepatic Impairment: Patients with moderate or severe liver impairment require caution and supervision, and a dose reduction should be considered due to significantly decreased drug clearance.
  • Elderly Patients: The daily dose should generally not exceed 30 mg in patients aged 65 and older.
  • Pregnancy and Infants: Use during pregnancy is generally not recommended, and use is avoided/not established for children younger than 1 year of age.

What should I know about interactions with other medicines?

The official regulatory documents for Lansoprazole define its interaction profile primarily through its effect on gastric acidity, enzyme metabolism, and specific timing requirements.

Co-administration with medicines that rely on an acidic environment for solubility is restricted. This includes a formal contraindication with Rilpivirine-containing products due to the risk of substantially reduced plasma concentrations of the antiviral. Similarly, other pH-dependent drugs, such as the antifungals Ketoconazole and Itraconazole, may have their effectiveness decreased by Lansoprazole’s acid-suppressing action.

Lansoprazole is also involved in enzyme-mediated interactions. It is documented as an inhibitor of the CYP2C19 enzyme, which can lead to an increase in plasma concentrations of co-administered drugs like Cilostazol. Conversely, strong enzyme inducers such as Apalutamide and the herbal product St. John's wort can decrease Lansoprazole exposure.

Certain combinations require strict monitoring or timing separation. Concomitant use with Warfarin or high-dose Methotrexate necessitates close oversight of blood concentrations. Regulatory labels mandate that Lansoprazole must be administered at least 30 minutes prior to Sucralfate to prevent reduced absorption.

Mechanism of Action

How Lanzo Works

Lanzo's mechanism is characterized by its function as a substituted benzimidazole that acts as a prodrug. It selectively accumulates and is activated within the acidic environment of the secretory canaliculi of the gastric parietal cells. The activated compound then targets the H+/K+-ATPase enzyme, known as the proton pump, which is the terminal molecular mechanism for acid secretion. Lanzo forms a covalent bond with sulfhydryl groups on the enzyme, resulting in the pump's irreversible inactivation. This non-competitive interaction leads to the complete cessation of hydrogen ion (H^+) transport into the gastric lumen.

This binding is permanent, requiring the parietal cell to synthesize and incorporate new proton pumps into its membrane for acid secretion to resume. The ensuing persistent inhibition of the H^+/K^+-ATPase results in a sustained and profound elevation of gastric pH, effectively altering the chemical environment within the upper gastrointestinal lumen.

Dosage and Administration Information

How Lanzo is Used: Official Administration Guidelines

Lanzo (Lansoprazole) is primarily administered via the oral route, typically as delayed-release capsules or orally disintegrating tablets (ODT), in official strengths of 15 mg or 30 mg. An intravenous (IV) formulation may be used in hospital settings when oral administration is not feasible.


Standard Dosing and Frequency

Most adult regimens require taking the medicine once daily (q.d.), though specific multi-drug treatments, such as those for H. pylori eradication, mandate divided doses (e.g., 30 mg twice daily or three times daily).

Administration Pattern Typical Adult Dose Range
Short-term therapy (up to 8 weeks) 15 mg or 30 mg once daily
Long-term maintenance 15 mg once daily
Pathological Hypersecretion (Zollinger-Ellison Syndrome) Starting at 60 mg once daily, up to 180 mg in divided doses

Administration and Timing Rules

The medicine must be taken before eating for optimal effect, usually 30 to 60 minutes before the first meal of the day. The delayed-release formulations, which contain enteric-coated granules, must not be crushed or chewed. This procedural restriction is critical to ensure the integrity of the coating is maintained until the medicine reaches the small intestine.

For patients with swallowing difficulties, the granules from the capsule may be sprinkled onto soft foods or mixed with specific fruit juices, or the ODT may be placed on the tongue to disintegrate, but the intact granules must be swallowed immediately.


Population-Specific Instructions

  • Pediatric Use: Dosing for children (1 to 11 years) is weight-dependent, with doses of 15 mg or 30 mg once daily.
  • Hepatic Impairment: For patients with severe liver impairment, a reduced daily dose of 15 mg once daily may be recommended, as clearance of the medicine is prolonged in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lanzo

This overview explains the structure of the official research evidence for Lanzo (Lansoprazole), focusing on the types of clinical studies that have been conducted, the outcomes researchers measured, and where scientific uncertainties remain. This information describes what has been observed in group settings and does not provide clinical guidance or predict individual results.

Research Evidence for Acid Reflux and Heartburn (GORD/GERD)

Research has widely explored Lanzo's use in conditions characterized by fluctuating or episodic manifestations, such as Gastro-Oesophageal Reflux Disease (GORD) and frequent heartburn. These studies were primarily designed as Randomized Controlled Trials (RCTs), comparing Lanzo to a placebo and other acid-reducing medicines. Findings describe patterns observed in the studies, where those receiving Lanzo reported measurements of symptom change that differed from those receiving placebo. Research explored comparative measurements of symptom reporting against other existing medicines, where findings varied across different studies and patient populations.


Research Evidence for Healing and Preventing Esophageal Damage (Erosive Esophagitis)

Lanzo was evaluated in studies examining its role in healing the lining of the food pipe when it has been damaged by acid (Erosive Esophagitis). Short-term RCTs focused on the healing phase, monitoring the objective outcome of endoscopic healing rate—the percentage of patients achieving complete mucosal repair, confirmed by an internal examination. Research highlights that studies reported a lower measurement of damage recurrence among patients who achieved initial healing compared to control groups during the observed follow-up periods.


Research Evidence for Stomach and Duodenal Ulcer Management

For active ulcers, studies monitored the short-term healing process. Outcomes related to physical discomfort were studied, along with the main objective of confirming the endoscopic closure of the ulcer. The medicine was also studied for its use as a core component of combination therapy for H. pylori eradication. Studies report how eradication of the bacteria was observed in studies monitoring measurements of subsequent duodenal ulcer recurrence.


Studies in Special Populations and Rare Conditions

For extremely rare conditions like Zollinger-Ellison Syndrome (ZES), which involve high physiological strain, evidence is primarily derived from long-term observational studies. These studies examined the measurement of excessive gastric acid production, specifically monitoring changes in basal acid output (BAO) relative to predefined physiological parameters. Data for certain groups remain insufficient, especially for long-term use in all pediatric populations, where results apply only to the populations studied.

Key Studies & References Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Frequently Asked Questions (FAQ)

Common questions about Lanzo (FAQ)


Q: How quickly should I expect Lanzo to start relieving symptoms?

A: Lanzo (Lansoprazole) is not intended for immediate relief of symptoms. Official product information indicates that it may take between one to four days for the full therapeutic effect to be observed. However, some individuals may report experiencing complete relief of symptoms within the first 24 hours.


Q: Is it normal to feel a bit light-headed when first starting Lanzo?

A: Dizziness is listed in the official prescription information as a common side effect of Lanzo. Furthermore, the over-the-counter label advises that if heartburn occurs along with lightheadedness, sweating, or dizziness, consultation with a health professional is advised, as these may be signs of a more serious condition.


Q: Does Lanzo cause any common digestive side effects, like diarrhea or constipation?

A: Yes, regulatory documents list several common gastrointestinal side effects reported in clinical trials (affecting 1% to 10% of adults). These include diarrhea, constipation, abdominal pain, flatulence, nausea, and vomiting.


Q: What are the long-term effects of taking Lanzo?

A: Official warnings describe specific risks associated with long-term use, typically defined as one year or longer. These duration-dependent risks include an increased regulatory risk for fractures related to osteoporosis (in the hip, wrist, or spine), low serum magnesium levels (hypomagnesemia), and potential difficulty absorbing Vitamin B12.


Q: Is Lanzo safe for people who have kidney issues?

A: A type of kidney inflammation called Acute Tubulointerstitial Nephritis (TIN) has been observed in patients taking medicines in this class (PPIs). However, official product information indicates that no general dose adjustment is required for adult patients who have significant pre-existing renal (kidney) failure. Consultation with a health professional is generally appropriate for those with kidney concerns.


Q: What happens if I miss a dose of Lanzo?

A: The primary regulatory documents do not contain standardized instructions for a missed dose. General patient guidance related to missed doses often follows the principle of taking the dose upon remembering, unless the next dose is imminent. Specific instructions should be sought from the prescribing physician.


Q: Is there a generic version of Lanzo available?

A: Yes. According to the FDA’s approved drug product information, generic versions of Lansoprazole (the active ingredient in Lanzo) are available for both the delayed-release capsules and the orally disintegrating tablets.


Q: What are the signs of an allergic reaction to Lanzo?

A: Signs of a severe allergic reaction (hypersensitivity) may include skin reddening, rash, or blisters. The medicine is formally contraindicated, meaning it must not be used, by individuals with a known severe hypersensitivity to Lansoprazole or any of its components.


Q: Does Lanzo make you feel tired or fatigued?

A: Fatigue is not listed in official documents as a common side effect (occurring in 1% or more of patients). However, other common nervous system side effects that could potentially affect energy levels, such as headache and dizziness, are reported.


Q: Is it common for people to experience joint pain while taking Lanzo?

A: Joint pain is not explicitly listed as a common (1% or greater) side effect. However, the over-the-counter label advises that if a rash or joint pain develops, consultation with a health professional is recommended. Musculoskeletal disorders are also listed in postmarketing adverse reaction reports.


Q: What are the most serious, but rare, side effects of Lanzo?

A: Official regulatory warnings list several serious adverse reactions. These include Acute Tubulointerstitial Nephritis (TIN), which is a form of kidney inflammation, severe Cutaneous Adverse Reactions (SCARs), and severe hypomagnesemia, which is an abnormally low level of magnesium in the blood.


Q: Will taking Lanzo mask symptoms of a more serious condition?

A: Official warnings state that a patient’s positive response to Lanzo does not rule out the possibility of a gastric malignancy (stomach cancer). If a patient has a suboptimal response to therapy, additional follow-up and diagnostic testing may be considered by a healthcare provider.


Q: Are there any specific warnings for women who are pregnant or breastfeeding regarding Lanzo?

A: The over-the-counter label states that individuals who are pregnant or breastfeeding should consult a health professional before use. Furthermore, the prescription label states that use during pregnancy is generally not recommended.


Q: Why is Lanzo sometimes prescribed for H. pylori infection?

A: Lanzo (Lansoprazole) is approved as a core component of combination therapy that includes antibiotics. This specific regimen is indicated for the purpose of eradicating the extitH. pylori bacterium, which helps reduce the risk of duodenal ulcer recurrence.


Q: Are there any specific vitamins or minerals that Lanzo might interfere with?

A: Yes, official warnings for long-term use (typically one year or longer) address the potential for malabsorption of Vitamin B12. There is also a risk of low serum magnesium levels (hypomagnesemia) reported with long-term use.


Q: Do I need to change my diet while taking Lanzo?

A: While the primary focus is on taking the medicine correctly, the over-the-counter label includes general lifestyle tips for managing heartburn. These include advice to avoid or limit certain foods and drinks that commonly trigger heartburn, such as spicy, fatty, or fried foods, as well as caffeine and alcohol.


Q: Can I drink coffee or alcohol while taking Lanzo?

A: The over-the-counter label advises avoiding or limiting both coffee (caffeine) and alcohol as general measures to help manage heartburn symptoms. Additionally, the label for one specific formulation explicitly states that the medicine should not be taken with alcohol.


Q: Is Lanzo ever used for conditions other than acid reflux?

A: Yes. Beyond typical acid reflux conditions, approved uses for Lanzo include the treatment of duodenal and gastric ulcers, combination therapy for extitH. pylori infection, and the treatment of Pathological Hypersecretory Conditions, such as Zollinger-Ellison Syndrome.


Q: Are there any herbal supplements I should avoid while taking Lanzo?

A: Official drug interaction warnings explicitly mention the herbal product St. John’s wort. The product information advises avoiding this supplement, as it is known to be a strong enzyme inducer that can decrease Lansoprazole exposure, potentially making it less effective.


Q: Does Lanzo interact with any common anti-depressant medications?

A: Lansoprazole is known to inhibit the CYP2 C19 enzyme, which is involved in the metabolism of many medicines. The regulatory label notes that this can increase the concentration of drugs that depend on this enzyme for breakdown; however, specific common antidepressants are not explicitly listed.


Q: Will Lanzo change the results of any lab blood tests?

A: Official warnings state that PPI therapy, including Lanzo, may lead to false-positive results when screening urine tests for THC. The medicine may also interfere with certain diagnostic tests that screen for neuroendocrine tumors.


Q: Is Lanzo an over-the-counter medication or only available by prescription?

A: Both prescription and over-the-counter ( OTC) versions are available. The OTC formulation is specifically approved for the short-term treatment of frequent heartburn, which is defined as heartburn occurring two or more days per week.


Q: Do research studies show Lanzo is better absorbed when taken at a specific time of day?

A: Clinical pharmacology studies demonstrate that the medicine’s absorption and overall exposure are significantly diminished—by approximately 50% to 70%—if it is taken 30 minutes after food, compared to taking it in a fasting condition.


How should Lanzo be stored and disposed of?

Storage and Disposal Requirements

Lanzo (lansoprazole) must be stored in a closed container at room temperature, typically defined as 20 C to 25 C (68 F to 77 F), with permitted excursions. Storage requirements strictly mandate that the medicine be protected from moisture, excessive heat, and direct light, and it must be kept from freezing.

All forms of the medicine must be stored out of the reach of children. Specifically, Orally Disintegrating Tablets (ODT) should be kept in their original container.

For disposal, do not flush unused or expired Lanzo down a toilet or pour it into a drain unless instructed to do so. The medicine must be discarded according to local regulations and official guidance, which typically requires consulting a healthcare professional or using a drug take-back option.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanzo found in:

A-Z Index: